Westlake Village, California, August 20, 2026
Turn Therapeutics announced new peer-reviewed research providing in-vivo evidence that GX-03 selectively reduces key inflammatory signals associated with skin inflammation and itch. Published in Life, the study evaluated the company’s lead investigational topical therapy in a murine dermatitis model following standardized Staphylococcus aureus exposure. The findings showed that pretreatment with GX-03 reduced several cytokines involved in the inflammatory response, including IL-36α and IL-36γ by approximately 50%, IL-31 by nearly 68%, and IL-4 by 16.7%. These biological changes were accompanied by a 66% reduction in clinical dermatitis severity compared with untreated animals. The study provides new mechanistic evidence for Turn Therapeutics’ strategy of modifying the local skin environment before inflammation becomes fully established. For cGxP.wire readers tracking dermatology research and localized therapeutic development, the key finding is the selective cytokine response observed with GX-03 rather than broad suppression of every inflammatory pathway evaluated. Notably, IL-13 remained essentially unchanged, suggesting that the treatment produced a more selective biological profile in the experimental model. The findings add preclinical evidence to the development rationale for GX-03 as a localized, non-systemic approach for inflammatory skin disease, while clinical evaluation remains necessary to determine whether these effects translate into meaningful benefit in patients.
GX-03 Reduces Multiple Inflammatory Signals
The research showed that GX-03 pretreatment significantly reduced several inflammatory cytokines linked to dermatitis and itch following the standardized skin challenge. IL-36α expression decreased by 49.9%, while IL-36γ decreased by 50.9%, indicating approximately half the release of these early inflammatory signals compared with untreated animals. The study also found a 67.7% reduction in IL-31, a cytokine closely associated with itch in inflammatory skin conditions including atopic dermatitis. IL-4, another important immune signaling molecule, was reduced by 16.7%. These changes were accompanied by a reduction in measured disease severity, with the mean vIGA-AD score declining from 2.44 in untreated animals to 0.83 following GX-03 pretreatment. The resulting 66% reduction in clinical dermatitis severity provides a second biological measure alongside the cytokine findings. Importantly, the study did not show a significant difference in IL-13, indicating that GX-03 did not uniformly suppress all measured inflammatory pathways. The selective nature of the cytokine changes is central to the study’s findings, because Turn is developing GX-03 around the concept of influencing the inflammatory environment locally rather than producing broad systemic immune suppression. These results remain experimental and were generated in an animal model, so their clinical relevance must be established through human trials.
Study Examines Early Intervention in Skin Inflammation
A notable feature of the research was the timing of GX-03 administration. Researchers applied the topical therapy for four days before exposing the animals to a standardized Staphylococcus aureus challenge designed to trigger atopic dermatitis-like inflammation. The experimental design allowed investigators to examine whether modifying the local skin environment before inflammatory activation could influence the severity and pattern of the subsequent response. The study evaluated 40 mice, with 18 animals in each group included in the final analysis following predefined exclusions. Animals receiving GX-03 pretreatment developed substantially less severe dermatitis than untreated controls. Researchers also assessed local tolerability during the pretreatment period and reported no local irritation, dryness, redness, barrier disruption or other adverse skin findings in the GX-03 group. For cGxP.wire, the research is particularly relevant because it explores a different timing-based approach to inflammatory skin disease: intervening before the inflammatory cascade becomes fully established. However, the study does not demonstrate preventive efficacy in human atopic dermatitis and should not be interpreted as clinical proof. The major value of the publication is mechanistic and preclinical, providing additional evidence that localized GX-03 exposure can alter selected inflammatory signals and disease severity following an experimental skin challenge.
Advertisement
Turn Advances Localized Topical Therapy Program
GX-03 is Turn Therapeutics’ lead investigational topical therapy for atopic dermatitis and is designed to act locally in the skin. The company is evaluating whether modifying the local skin environment can reduce inflammatory signaling while avoiding the broad systemic immune effects associated with some approaches to inflammatory disease. The newly published research strengthens the biological rationale behind this strategy by demonstrating selective reductions in IL-36, IL-31 and IL-4 together with reduced dermatitis severity in an animal model. Turn is also advancing GX-03 through a randomized, double-blind, vehicle-controlled clinical trial in atopic dermatitis, where human safety and efficacy data will be required to validate the preclinical findings. The publication therefore represents an important research milestone but not a regulatory or clinical efficacy milestone. The central development question remains whether the cytokine modulation observed in the murine model can translate into reduced inflammation, itch and disease severity in patients. For the dermatology development field, the program highlights continued interest in topical therapies designed to act locally and selectively within diseased skin. As Turn progresses its clinical program, future human data will determine whether the upstream inflammatory-modulation concept demonstrated in this study can support further development of GX-03 as a potential treatment for atopic dermatitis and other inflammatory skin diseases.
Source:Turn Therapeutics press relese
